Effects of deferasirox–deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload

Yesim Aydinok, 1 Antonis Kattamis, 2 M Domenica Cappellini, 3 Amal El-Beshlawy, 4 Raffaella Origa, 5 Mohsen Elalfy, 6 Yurdanur Kilinç, 7 Silverio Perrotta, 8 Zeynep Karakas, 9 Vip Viprakasit, 10 Dany Habr, 11 Niculae Constantinovici, 12 Junwu Shen 11 and John B Porter, 13 on behalf of the HYPERION investigators

1 Ege University Hospital, Izmir, Turkey; 2 First Department of Pediatrics, University of Athens, Athens, Greece; 3 Università di Milano, Ca Granda Foundation IRCCS, Milan, Italy; 4 Cairo University, Cairo, Egypt; 5 Ospedale Regionale per le Microcitemie, Cagliari, Italy; 6 Ain Shams University, Cairo, Egypt; 7 Cukurova University, Medical Facility, Adana, Turkey; 8 I° Policlinico II° Università di Napoli, Naples, Italy; 9 Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey; 10 Department of Pediatrics and Thalassemia Center, Siriraj Hospital, Mahidol University, Bangkok, Thailand; 11 Novartis Pharmaceuticals, East Hanover, NJ, USA; 12 Novartis Pharma AG, Basel, Switzerland; 13 University College London, London, United Kingdom.

Corresponding author: Yesim Aydinok, Ege University Hospital, Izmir, Turkey.
Email: yesim.aydinok@ege.edu.tr Tel: (+) 90 232 390 1029. Fax: (+) 90 232 343 8090

Short title: Combined DFX–DFO in transfusional iron overload

Abstract word count: 227/250

Tables/figures: 3 tables / 6 figures (limit: 7 figures)

References: 35 (limit: 100)
Key points

- DFX–DFO combination followed by DFX monotherapy led to a meaningful decrease in myocardial and liver iron in patients with severe siderosis
- Substantial liver iron reduction might be helpful in patients requiring rapid control of liver iron (eg pretransplant or planned pregnancy)
Abstract

Deferasirox (DFX) monotherapy is effective for reducing myocardial and liver iron concentrations (LIC), although some patients may require intensive chelation for a limited duration. HYPERION, an open-label, single-arm, prospective Phase II study (NCT01254227) evaluated combination DFX–deferoxamine (DFO) in patients with severe transfusional myocardial siderosis (mT2* 5≤<10 ms; LVEF ≥56%) followed by optional switch to DFX monotherapy when achieving mT2* >10 ms. Mean dose was 30.5 mg/kg/day DFX and 36.3 mg/kg/day DFO on a 5-day regimen. Geometric mean mT2* ratios (GmeanMonth12/24/Gmeanbaseline) were 1.09 and 1.30, respectively; increasing from 7.2 ms at baseline (n=60) to 7.7 ms at 12 (n=52) and 9.5 ms at 24 months (n=36). 17/60 patients (28.3%) achieved mT2* ≥10 ms and ≥10% increase from baseline at Month 24; 15 opted to switch to monotherapy during the study based on favorable mT2*. LIC decreased substantially from a baseline of 33.4 to 12.8 mg Fe/g dw at Month 24 (–52%). LVEF remained stable with no new arrhythmias/cardiac failure. Five patients discontinued with mT2* <5 ms and one died (suspected central nervous system infection). Safety was consistent with established monotherapies. Results show clinically meaningful improvements in mT2* in approximately one-third of patients remaining on treatment at Month 24, alongside rapid decreases in LIC in this heavily iron-overloaded, difficult-to-treat population. Combination therapy may be useful when rapid LIC reduction is required, regardless of myocardial iron overload.

Keywords: thalassemia, deferasirox, deferoxamine, iron overload, chelation
Introduction

Patients with transfusional iron overload are at risk of developing myocardial iron deposition. Severe myocardial iron overload (myocardial [m]T2* <10 ms) is associated with a substantially increased risk of heart failure.1-3 As such, some patients may require intensified chelation4 for a limited duration to expedite transition from a high- to low-risk status for heart failure (mT2* <10 ms to ≥10 ms).1

Significant reduction of total body iron overload, including clinically relevant decreases in myocardial iron, has been demonstrated with deferasirox (DFX) or deferoxamine (DFO) monotherapy in transfusion-dependent thalassemia patients with mild, moderate and severe myocardial iron overload.5-11 However, suboptimal myocardial responses to DFX have been identified in patients with severe myocardial and liver iron deposition, who may, therefore, require more aggressive therapy.12 Long-term continuous intravenous DFO monotherapy has been explored in patients at high risk of cardiac toxicity, although compliance remains an issue.13 Combination therapy with deferiprone and DFO has also been reported in both prospective and retrospective studies and shown substantial improvement in myocardial iron burden.14-17 Small studies using combination DFX–DFO therapy have shown a rapid reduction in systemic and myocardial iron with no increase in toxicity.18-21 However, few patients assessed with any combination therapy to date have had severe total body iron burden as reflected by significant elevations in both liver and myocardial iron.

Combined modalities may increase the rate of iron removal from both the liver and myocardial tissues and further investigation into combination regimens could permit the use of lower doses of individual chelators versus monotherapy, thereby reducing the potential for unwanted side effects. Improved definition of the clinical circumstances that may benefit most from combination therapy will help optimize a tailored approach to
patient treatment. As thalassemia patients require life-long chelation therapy, patient satisfaction and adherence should also be considered. Ultimately, the objective should be to maintain a normalized iron burden with oral monotherapy instead of cumbersome combination therapy. However, greater understanding of when patients can switch from combination to monotherapy is needed. The current study was designed to evaluate a treatment regimen of combined DFX and DFO therapy in patients with severe transfusional myocardial siderosis, followed by DFX monotherapy when patients reached a lower risk status for heart failure, over a 24-month period. The primary objective was to evaluate the effect of this treatment modality on myocardial iron content as depicted by change in mT2* at Month 12.
Methods

Patients

HYPERION (NCT01254227) was conducted between January 2011 and November 2013. Inclusion criteria were: patients aged ≥10 years with β-thalassemia major, Diamond–Blackfan anemia (DBA) or congenital sideroblastic anemia on chronic transfusion therapy with cardiovascular magnetic resonance (CMR)-measured mT2* 5 to <10 ms; CMR-measured left ventricular ejection fraction (LVEF) ≥56%, R2-magnetic resonance imaging (MRI)-measured liver iron concentration (LIC) ≥7 mg Fe/g dry weight (dw) and serum ferritin ≥1000 ng/mL; a lifetime history of ≥50 units of red blood cell (RBC) transfusions and transfusional requirement of ≥8 units/year of RBC were also required.

Key exclusion criteria included clinical symptoms of cardiac dysfunction, serum creatinine above the upper limit of normal (ULN), significant proteinuria (urinary protein/creatinine ratio [UPCR] ≥1.0 mg/mg) and alanine aminotransferase (ALT) levels >5 x ULN, but only if LIC was <10 mg Fe/g dw.

Study design

HYPERION was a 24-month prospective, Phase II, open-label, single-arm, multi-center study. Eligible patients had a 5-day washout period followed by a starting daily dose of oral DFX 20 mg/kg in combination with infused DFO 40 mg/kg, for 5 days/week for ≥8 hours/day.

Dose escalation of DFO was not permitted. DFX dose was increased to 30 and then 40 mg/kg/day at the end of Month 1 and 6, respectively, unless any criteria for dose reduction or drug interruption were met (eg drug-related adverse events [AE]). Downwards dose adjustments for both drugs were advised based on LIC, serum ferritin,
renal and hepatic laboratory parameters, gastrointestinal AEs, rash, auditory and ocular abnormalities, or infection.

Patients achieving mT2* ≥10 ms with a relative mT2* increase of ≥10% from baseline after 6 months had the option to switch to DFX monotherapy (30–40 mg/kg/day). Combination therapy was resumed with the highest tolerable DFX and DFO dose if mT2* fell to <10 ms with a relative decrease of ≥10% from previous mT2* value. Both DFX and DFO were to be interrupted, with continued monitoring of LIC and mT2*, if serum ferritin was confirmed <200 ng/mL or LIC was <1.5 mg Fe/g dw.

The study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki and was approved by institutional ethics committees at participating sites. Written informed consent was obtained prior to any screening procedures.

Endpoints

The primary efficacy endpoint was change in mT2* assessed by the ratio of the geometric mean (Gmean) mT2* at Month 12 divided by that at baseline (Gmean_{12}/Gmean_{baseline}). A key secondary endpoint was the proportion of patients achieving mT2* ≥10 ms and a ≥10% relative increase from baseline at Months 6, 12, 18 and 24. Other secondary endpoints were change in mT2* and change in LVEF at Month 24; time to achieve mT2* ≥10 ms (with ≥10% relative increase from baseline); and safety assessments.

Assessments

Efficacy was analyzed according to the study protocol for all evaluable patients in the full analysis set (FAS), defined as patients who received at least one dose of study drug and had a baseline and post-baseline assessment within each visit window. Last observation
carried forward (LOCF) was used at Month 12 when analyzing mT2* data on the evaluable subset of the FAS.

mT2* and LVEF were measured by CMR; and LIC was measured using a validated R2 MRI technique at baseline and 6-monthly visits up to Month 24. Serum ferritin was assessed monthly. Patients without baseline data or any post-baseline value in a visit window were excluded from analysis at that time point. Myocardial iron concentration (MIC) was derived from mT2* values based on the formula described by Carpenter et al. (2011).

The safety set consisted of all patients who received at least one dose of study drug and had at least one post-baseline assessment. Safety was evaluated through continuous monitoring and recording of AEs, serious AEs, laboratory testing and clinical evaluations; with biweekly assessments for the first 2 months of treatment. Both efficacy and safety assessments included patients who remained on combination therapy and those who switched to monotherapy during the study.

Statistical methods

A sample size of 45 enrolled patients was required to obtain a two-sided 95% confidence interval (CI) for the ratio of mT2* at Month 12 divided by mT2* at baseline (Gmean/meanbaseline) with a half-width of 0.065 on the log-scale assuming lognormal distribution of mT2*, standard deviation of 0.2 on the log-scale and 20% drop-out rate. For the primary efficacy endpoint, the Gmean (Gmean/meanbaseline) was presented with a 95% CI. Efficacy analyses were summarized descriptively. A post-hoc analysis of the intention-to-treat (ITT) population was also performed for the endpoint relating to the proportion of patients achieving mT2* ≥10 ms and a ≥10% relative increase from baseline.
Results

Patients

Of 312 patients screened, 60 were enrolled (59 with \(\beta\) thalassemia major and one with DBA; Table 1). Thirty-four (56.7%) patients completed 24 months of treatment, with the majority of discontinuations in the first 12 months of the study (n=21; Figure 1). Five patients discontinued due to confirmed mT2* <5 ms as per protocol; of these, four patients had mT2* <6 ms at baseline, and one patient had mT2* of 6.1 ms at study entry. Patients with a single assessment of mT2* <5 ms or LVEF <56% are discussed in the Supplementary Information. Other main reasons for discontinuation included loss to follow-up (n=6) and consent withdrawal (n=6; including personal reasons such as relocation and inability to visit the investigational site).

Patients had substantial iron overload at baseline; 68.3% of patients had LIC >30 mg Fe/g dw with a mean LIC of 33.4 ± 14.5 mg Fe/g dw, and \(G_{\text{mean baseline}}\) mT2* was 7.2 ms (95% CI: 6.83, 7.58). Median serum ferritin was 5551 ng/mL. All patients had a LVEF \(\geq 56\%\) at baseline; by Westwood criteria, \(^{26}\) most patients (85.0%) had a LVEF at or above the lower limit of normal (LLN).

Exposure to treatment and compliance

Overall, 15 patients (25.0%) switched to DFX monotherapy at some point during the study based on favorable mT2* values; seven patients switched in Month-6, four in Month-12, one in Month-18 and three in Month-24 visit windows. Two patients who first switched to monotherapy during Month 6, then switched back to combination therapy during Month 12 and 19, respectively. As planned in the study design, these patients are evaluated together with the patients continuing combination therapy.
Average actual DFX and DFO doses over the first 12 months were 29.6 ± 6.3 mg/kg/day and 37.4 ± 5.8 mg/kg/day (normalized to a 5-day regimen; 26.7 ± 4.1 mg/kg/day for a 7-day regimen), respectively. Average dose was similar throughout the 24-month study (30.5 ± 7.1 mg/kg/day DFX and 36.3 ± 6.7 mg/kg/day for DFO). Monthly mean actual dose is shown in Figure 2. The median (range) duration of exposure was 719.0 days (21.0–737.0) for DFX and 407.5 days (29.0–737.0) for DFO, with a total exposure of 86.9 and 72.7 patient-years, respectively.

Of all patients enrolled (n=60), 99.4 ± 4.9% of the planned DFX dose and 97.6 ± 12.7% of the planned DFO dose were taken. DFX or DFO treatment was interrupted at least once in 36 (60.0%) and 28 (46.7%) patients, respectively. Interruption was most commonly due to AEs (n=27 [45.0%] for DFX and n=20 [33.3%] for DFO). Per-protocol interruptions due to efficacy included those for DFX, which were implemented in two patients (serum ferritin <200 ng/mL, LIC <3 mg Fe/g dw; n=1 each) and for DFO in seven patients (LIC <3 mg Fe/g dw, serum ferritin <1000 ng/mL; n=1 each and other; n=5). One patient interrupted both DFX and DFO as a result of LIC <1.5 mg Fe/g dw at Month 18. Median (range) duration of interruption for DFX and DFO was 6.7 (1.0–57.0) and 6.6 (1.5–370.0) days, respectively.

DFX or DFO dose was reduced at least once in 32 (53.3%) and 37 (61.7%) patients, respectively; the main reasons for dose reduction were in response to an AE (n=26 [43.3%] and n=19 [31.7%], respectively); per protocol (n=4 [6.7%], n=18 [30.0%], respectively); dosing error (n=1 [1.7%], each) and other (n=5 [8.3%], each). Patients could have had more than one reason for dose reduction.

**Average iron intake**

Average iron intake was <0.3 mg/kg/day for 46.7% patients (n=28), 0.3–0.5 mg/kg/day in 24 (40.0%) patients and >0.5 mg/kg/day in 11.7% (n=7) patients (data missing, n=1).
Efficacy

Myocardial iron removal

In the FAS, Gmean mT2* increased from 7.2 ms at baseline (n=60) to 7.7 ms at Month 12 (n=52; Gmean ratio 1.09 [95% CI: 1.04, 1.15]; median change from baseline 0.7, range –3.1 to 4.5) indicating a 9% improvement from baseline. Eight patients did not have a post-baseline mT2* measurement and were therefore not evaluable at Month 12. Gmean mT2* continued to increase to 9.5 [8.5, 10.6] ms at Month 24 (n=36). Ratio of Gmeans was 1.30 (95% CI: 1.17, 1.44; Figure 3), indicating a 30% improvement from baseline (median change from baseline 2.4 ms, range –2.4 to 10.0).

MIC remained steady from a baseline of 4.2 ± 1.0 (n=60) to 4.3 ± 1.4 mg Fe/g dw at Month 6 (n=48), but decreased to 3.9 ± 1.4 mg Fe/g dw at Month 12 (n=46; change from baseline –0.3 ± 0.9 [95% CI: –0.62, –0.07]; –8.3%), and to 3.1 ± 1.4 mg Fe/g dw at Month 24 (n=36; –0.9 ± 1.3 [95% CI: –1.35, –0.51]), a 22.2% decrease.

The proportion of patients achieving mT2* ≥10 ms and ≥10% relative increase from baseline, based on the FAS (evaluable patients who remained on treatment with an assessment within each visit window or LOCF at Month 12) was 12.5% at Month 6 (n=6/48 [95% CI: 5.9, 24.7]); 19.2% (n=10/52 [95% CI: 10.8, 31.9]) at Month 12; 33.3% (n=11/33 [95% CI: 19.8, 50.4]) at Month 18; and 47.2% (n=17/36 [95% CI: 32.0, 63.0]) at Month 24 (Figure 4). When including all patients enrolled in a post-hoc ITT analysis, the proportions were 10.0% at Month 6 (n=6/60 [95% CI: 4.7 20.2]), 16.7% (n=10/60 [95% CI: 9.3, 28.0]) at Month 12, 18.3% (n=11/60 [95% CI: 10.6, 29.9]) at Month 18 and 28.3% (n=17/60 [95% CI: 18.5, 40.8]) at Month 24 (Figure 4). Overall, 21 patients achieved an mT2* value of ≥10 ms and a ≥10% relative increase from baseline at any time in the study, with a median time to response of 722 days.
Of 32 patients with baseline mT2* 6 to <10 ms and with an assessment within the Month 24 visit window, 17 (53.1%) improved to mT2* ≥10 ms, 13 (40.6%) remained within the same category, and two patients (6.3%) worsened with mT2* <5 ms. Of four patients with mT2* 5 to <6 ms at baseline and with an assessment within the Month 24 visit window, three patients improved to between 6 and <10 ms at Month 24 and one patient worsened with mT2* <5 ms. Of 10 patients with baseline mT2* 5 to <6 ms, three completed the study, four discontinued as a result of mT2* <5 ms as per protocol, one was lost to follow-up and two withdrew consent as a result of personal reasons.

Improvements in mT2* were observed across all baseline iron loading subgroups examined (Table 2). Careful interpretation of findings in the lower serum ferritin subgroup in particular is needed as the sample size is small.

**Liver iron removal**

Mean ± standard deviation (SD) LIC decreased by 9.2 ± 8.7 mg Fe/g dw at Month 6 (n=50) from a baseline of 33.4 ± 14.5 mg Fe/g dw. LIC reduction continued with a 46.4% decrease (change from baseline –14.4 ± 12.1 mg Fe/g dw) at Month 12 (n=40) and a decrease of 52.3% to 12.8 ± 11.7 mg Fe/g dw at Month 24 (n=35; –17.3 ± 15.0 mg Fe/g dw; Figure 3).

**Serum ferritin reduction**

Median (range) serum ferritin decreased from 5551 (1163–11,317) ng/mL at baseline to 2491 (108–11,508) ng/mL at Month 24 (n=34; change from baseline –2064 [–5750 to 3190] ng/mL; –43.9%; Figure 5).
Cardiac function

Mean LVEF remained stable and within the normal range after 2 years of treatment (change +0.9 ± 6.0%; Supplementary Figure I). No patient discontinued as a result of LVEF <50%, as per protocol, and none developed clinical heart disease or experienced arrhythmia during the study.

Safety parameters

Adverse events

Overall, 54 (90.0%) patients experienced an AE regardless of study drug causality (Table 3). AEs of special interest for treatment were proteinuria (n=6); increased blood creatinine (n=5); neurosensory deafness (n=3; additional detail in supplemental information), conductive deafness and bilateral deafness (n=2 each); increased ALT; increased aspartate aminotransferase; rectal hemorrhage; and decreased platelet count (n=1 each).

AEs (≥5%) suspected related to either drug or combination therapy by the investigator were abdominal pain, increased UPCR (≥1.0 mg/mg; each 8.3%), and increased serum creatinine, diarrhea and nausea (each 6.7%). Serious AEs irrespective of causality were reported in 17 (28.3%) patients, of which six events in four patients were considered drug related (calcium deficiency, drug rash with eosinophilia and systemic symptoms [DRESS] syndrome, abdominal pain, dermoid cyst, and altered state of consciousness and pyrexia).

Five discontinuations due to AEs were reported; abdominal pain (n=2), arthritis (n=1), pruritus (n=1), and suspected DRESS syndrome (n=1). Further evaluation by independent experts did not reveal a consensus for the diagnosis of DRESS. Twenty-
four hours after discontinuation, absolute eosinophil count and white blood cell count were normal at $0.1 \times 10^9/L$ and $5.7 \times 10^9/L$ in this patient.

No patient was reported to have cardiac failure or arrhythmia during the 2-year study. One patient died, attributed to a suspected central nervous system (CNS) infection. The patient had pyrexia with an altered state of consciousness suspected by the investigator to be related to infection and continuation of DFO treatment, although no autopsy was conducted and this could not be confirmed. The investigator stated that splenectomy and concomitant diabetes were contributory factors for the event. The majority of the AEs, including the patient death, were reported within the first 12 months of the study.

**Laboratory parameters**

Mean ± SD creatinine clearance levels remained within the normal range (Supplementary Figure II). Seven patients had two consecutive decreases in creatinine clearance (CrCl) to category 60–90 mL/min; one patient had two consecutive measurements below 60 mL/min; no patients had CrCl levels <40 mL/min. Two patients had two consecutive serum creatinine increases >33% above baseline and above the ULN, which were transient and resolved without intervention (n=1) and managed with dose interruption/reduction (n=1). Six (10.0%) patients had two consecutive measurements of UPCR >1.0 mg/mg, which either resolved without intervention (n=3) or required dose interruption and/or reduction (n=3).

Mean ± SD ALT decreased from a baseline of $82.6 \pm 59.1$ to $42.2 \pm 43.4$ U/L at Month 24 (n=34; absolute change from baseline $-33.0 \pm 52.2$ mg Fe/g dw; Figure 6). Two (3.3%) patients had two consecutive increases in ALT >5 x ULN and >2 x baseline.
Discussion

The objective of HYPERION was to evaluate the effectiveness of a DFX–DFO combination regimen in patients with severe myocardial siderosis, followed by DFX monotherapy in patients achieving mT2* ≥10 ms with a relative mT2* increase of ≥10% from baseline after 6 months. The underlying assumption behind the study design was that patients may benefit from combination therapy to rapidly remove iron when they are at risk of myocardial iron-related heart failure, but will adhere better over their life-long chelation regimen to oral monotherapy once they have moved into a lower risk strata for heart failure (mT2* >10 ms).

The population enrolled in HYPERION had high baseline liver and myocardial iron, with mean LIC of 33.4 mg Fe/g dw and Gmean mT2* of 7.2 ms. Findings showed that combination DFX–DFO, followed by DFX monotherapy where appropriate, resulted in robust and clinically relevant improvements in mT2* at 12 (9% improvement) and 24 months (30% improvement); although examination of the 95% CIs of the Month 12 and Month 24 absolute change in mT2* may suggest statistical significance, this descriptive study was not powered for hypothesis testing. Importantly, a rapid and substantial decrease in LIC was also observed. A substantial proportion of patients (25.0%) also achieved sufficient control of mT2* to enable switch to DFX monotherapy after a limited duration of combination therapy. Although seven of the 10 patients with baseline mT2* 5 to <6 ms discontinued, they may not all necessarily be considered treatment failures, since reasons for discontinuation included relocation and inability to visit the investigational site. Furthermore patients with mT2* 5 to <6 ms may be expected to have repeat measurements <5 ms due to the variability in CMR assessments at these values.

Myocardial iron removal with combination treatment was continuous, with an increasing proportion of patients who remained on the study achieving a clinically significant
improvement in mT2* ≥10 ms and a ≥10% relative increase from baseline at each time point. When considering all patients initially enrolled, this increase was still evident, although less pronounced. The differences between the results of the post-hoc ITT analysis and the pre-specified analysis of patients remaining on treatment is accounted for by the relatively high rate of patient discontinuations, predominantly due to withdrawal of consent (n=6) and loss to follow-up (n=6). Improvements in MIC were observed after 12 months of treatment in patients remaining on the study, in contrast to LIC where the decrease was rapid, with substantial changes evident from Month 6 onwards. These trends towards greater improvement of mT2* and MIC over time may have been influenced by continued treatment and permitted DFX dose increases after Month 6, highlighting the need for long-term treatment for myocardial iron removal, as well as dose adjustments based on both efficacy and safety parameters. These observations are also consistent with those of Noetzli et al. using other chelation regimens, where improvement in mT2* generally followed improvements in LIC. Nevertheless, mT2* improvements were observed across the full range of baseline liver iron burdens, highlighting the effectiveness of this treatment modality in treating a wide range of patients. While the improvement in mT2* was numerically greater in patients with baseline LIC <30 versus ≥30 mg Fe/g dw, there were insufficient patient numbers with low baseline LIC to systematically examine the influence of baseline LIC.

These findings need to be considered in the context of the heart, as one of the most sensitive organs to iron toxicity. Iron-related heart failure and death occur at tissue iron concentrations in the heart that are generally tolerated in the liver. Consequently, removal of a small amount of iron from the heart may have a greater impact on organ function compared with removal of an equivalent amount of liver iron. Furthermore, given the non-linear relationship between mT2* and MIC, proportional improvements in mT2*
from the low baseline levels in HYPERION relate to a larger degree of iron removal when compared with patients having higher baseline mT2*.

Importantly, while all patients had LVEF ≥56% at baseline, in patients remaining on treatment the mean LVEF remained stable throughout the study. There were also no new episodes of arrhythmias or cardiac failure reported, despite severe myocardial iron overload at baseline in all patients, imparting a high risk of heart failure within 12 months. Results highlight that appropriate chelation therapy can help manage this risk. Both high-dose DFO monotherapy and deferiprone–DFO combination therapy may have a role in treating thalassemia major patients with heart failure (LVEF <56%); the efficacy of DFX–DFO combination therapy in such a patient population requires further investigation.

Advances in the management of cardiac complications have led to a longer life expectancy in patients with transfusion-dependent anemias, and other complications, including those related to liver iron overload, are increasingly being seen as a cause of death. Therefore, the rapid and clinically significant decrease in liver iron burden from severe levels at baseline in HYPERION is important. When compared with previous studies of DFX monotherapy, the mean ± SD absolute reduction in LIC after 1 year of DFX–DFO combination therapy was considerably higher despite similar levels at baseline; −14.3 ± 11.9 (HYPERION study) versus −8.9 ± 11.4 (CORDELIA study) and −6.6 ± 9.9 mg Fe/g dw (EPIC). Although more research is needed, this combination therapy regimen may be appropriate for a select group of patients who require a rapid decrease in liver iron even in the absence of myocardial siderosis, including circumstances such as pre-bone marrow transplantation, planned pregnancy or when high doses of monotherapy are not well tolerated. Notably, LIC reduction was matched by an overall improvement in ALT levels reflecting possible improvement in liver function.
in these patients. Substantial reduction in LIC may have also influenced the extent of mT2\* improvement in some patients,\textsuperscript{27,33} particularly since the majority of patients had severe iron overload at baseline; this requires further study. Serum ferritin levels also decreased substantially, highlighting the reduction in total body iron stores with DFX–DFO treatment.

Although HYPERION was non-comparative and unblinded in nature, these results in a large patient population with severe total body iron burden expand on smaller pilot studies with DFX–DFO\textsuperscript{18,19,21} and provide insights into the combination treatment modality followed by less intensive monotherapy for a duration longer than 1 year. Tanner et al. have also reported on combined chelation therapy in patients with both mild-to-moderate\textsuperscript{17} and severe\textsuperscript{15} myocardial siderosis but using deferiprone and DFO. The latter study assessed 15 patients with severe iron overload including myocardial siderosis (mean mT2\* 5.7 ms and liver T2\* 3.7 ms), and showed significant improvements in mT2\* to 7.9 ms and in liver T2\* to 10.8 ms at 1 year. LVEF increased significantly from 51.2 to 65.6%. A more recent study in patients with severe myocardial siderosis and heart failure showed significant improvements in mT2\* and LVEF over time, but no differences between the DFO monotherapy and DFO–deferiprone combination arms.\textsuperscript{28} However, it is difficult to make comparisons between the studies given the differences in total body iron burden of the enrolled patients, as well as study design and clinical assessments. Furthermore, Tanner et al. evaluated a combination regimen throughout the study durations; whereas HYPERION evaluated a treatment modality of combination followed by monotherapy and reported results together for those patients receiving combination therapy throughout and those who switched to monotherapy.

Safety findings were consistent with the established safety profile of DFX and DFO, with no unexpected findings.\textsuperscript{8-10,34} Renal and hepatic AEs in particular were not increased
compared to previous reports of DFX monotherapy.\textsuperscript{10} Although the number of study discontinuations was higher than DFX monotherapy studies,\textsuperscript{5,6,10,35} particularly over the first 12 months, these discontinuations were largely due to logistical issues and not safety concerns. This is not unexpected since combination DFX–DFO therapy may be cumbersome, particularly while complying with the requirements of a clinical trial. Combination therapy should therefore be limited to as short a duration as possible, followed by monotherapy with deferasirox, which may be sufficient to control iron overload once patients have reached a lower-risk status for heart failure. Fifteen patients switched to monotherapy based on a favorable mT2* response (of whom two patients later returned to combination therapy). One of the difficult issues with cardiac management is whether to continue with combination therapy if severe body iron burden is reduced, for example if LIC is <5 mg Fe/g dw or serum ferritin is <1000 ng/mL, but mT2* is still below 10 ms. Data on such patients are still limited. The only death in the study was due to a suspected, but not confirmed, CNS infection. Pyrexia with an altered state of consciousness in this patient was suspected by the investigator to be related to DFO treatment. Patients in this study received high doses of DFO with dose reductions as serum ferritin decreased. Although audiometric changes seen here were not suspected to be related to treatment, patients receiving DFO and DFX, in combination or as monotherapy, should receive regular audiometric monitoring.

In conclusion, DFX–DFO combination therapy followed by DFX monotherapy, in cases with sufficient myocardial T2* improvement, with appropriate dose adjustments improved mT2* after 12 and 24 months of treatment. Furthermore, none of these high-risk patients who completed the study developed heart failure over 24 months. Importantly, there was a rapid and clinically meaningful reduction in liver iron in these patients with severe total body iron burden at baseline. The safety profile of both treatments in combination was clinically manageable with no additional safety concerns. Although further evaluation of
DFX–DFO combination therapy in ‘real-world’ clinical practice is desirable, it may be considered not only for the treatment of patients with severe transfusional myocardial siderosis requiring intensive chelation, but also in specific patients where a rapid reduction in liver iron is needed.
Acknowledgments

This study was funded by Novartis Pharma AG. We thank Debbi Gorman, PhD, of Mudskipper Business Ltd for medical editorial assistance. Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals.

Funding source

The study was sponsored by Novartis Pharma AG and designed by the sponsor in close collaboration with the study steering committee. The sponsor conducted the statistical analysis. Authors had full access to the data and participated actively in interpreting data and writing and critically reviewing the article with the assistance of a medical writer funded by the sponsor. The corresponding author had final responsibility for the manuscript content and decision to submit for publication.

Authorship contributions

YA, JBP, AK, AEB, ME, YK, SP, ZK, VV and RO served as investigators on this trial, enrolling patients. They contributed to data interpretation, reviewed and provided their comments on this manuscript. YA, JBP, AK and MDC served as Study Steering Committee members overseeing the conduct of the trial, from study design to analysis plan and data interpretation. DH and NC assisted in developing the trial protocol, coordinated the execution of the trial and contributed to the analysis, interpretation and reporting of the trial data. JS served as the trial statistician. All authors approved the final manuscript.
Disclosures

YA reports participation in speaker’s bureau and receiving research grant support and honoraria from Novartis Pharmaceuticals, and research grant support from FerroKin BioSciences Inc. JBP reports participation in advisory boards for Novartis Pharmaceuticals and is supported by the NIHR University College London Hospitals Biomedical Research Centre (BRC). AK reports received honoraria and research funding from Novartis Pharmaceuticals and participating in a speaker’s bureau. MDC reports participating in Novartis Pharmaceuticals advisory boards. AEB reports participation in speaker’s bureau, and receiving grant funding and honoraria from Novartis Pharmaceuticals; research grant funding and honoraria from Genzyme and ApoPharma Pharmaceuticals. RO received speaker’s honoraria from Novartis Pharmaceuticals. SP received research funding from Novartis Pharmaceuticals. ZK received research grants and speaker’s honoraria from Novartis Pharmaceuticals. VV received research grant support and lecture fees from Novartis Pharmaceuticals and research grant support from GPO-L-ONE, Thailand, FerroKin Biosciences and National Research University (NRU), Thailand. DH, NC and JS are employees of Novartis Pharmaceuticals. YK and ME have no relevant conflicts of interest to disclose.
References


Table 1. Demographic and baseline patient characteristics

<table>
<thead>
<tr>
<th>Variable</th>
<th>All patients (n=60)†</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Disease, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>β thalassemia major</td>
<td>59 (98.3)</td>
</tr>
<tr>
<td>DBA</td>
<td>1 (1.7)</td>
</tr>
<tr>
<td><strong>Age, years</strong></td>
<td></td>
</tr>
<tr>
<td>22.8 ± 7.3</td>
<td></td>
</tr>
<tr>
<td><strong>Median age (range), years</strong></td>
<td>22.0 (10.0–41.0)</td>
</tr>
<tr>
<td><strong>Male:female, n</strong></td>
<td>28:32</td>
</tr>
<tr>
<td><strong>Race, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>50 (83.3)</td>
</tr>
<tr>
<td>Black</td>
<td>1 (1.7)</td>
</tr>
<tr>
<td>Asian</td>
<td>9 (15.0)</td>
</tr>
<tr>
<td><strong>Hepatitis status, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>1 (1.7)</td>
</tr>
<tr>
<td>Hepatitis C</td>
<td>16 (26.7)</td>
</tr>
<tr>
<td>Hepatitis B and C</td>
<td>1 (1.7)</td>
</tr>
<tr>
<td>No hepatitis</td>
<td>42 (70.0)</td>
</tr>
<tr>
<td><strong>Time since start of blood transfusions, years</strong></td>
<td>22.3 ± 7.3</td>
</tr>
<tr>
<td><strong>Total number of blood transfusions received, n</strong></td>
<td>371.5 ± 161.6</td>
</tr>
<tr>
<td><strong>Previous chelation therapy, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>DFO</td>
<td>12 (20.0)</td>
</tr>
<tr>
<td>Deferiprone</td>
<td>8 (13.3)</td>
</tr>
<tr>
<td>DFX</td>
<td>20 (33.3)</td>
</tr>
<tr>
<td>DFO + deferiprone</td>
<td>18 (30.0)</td>
</tr>
<tr>
<td>Other‡</td>
<td>2 (3.3)</td>
</tr>
<tr>
<td><strong>Time since start of first chelation therapy, years</strong></td>
<td>18.6 ± 8.1</td>
</tr>
<tr>
<td>mT2*, ms</td>
<td></td>
</tr>
<tr>
<td>LIC categories</td>
<td>n (%)</td>
</tr>
<tr>
<td>----------------</td>
<td>-------</td>
</tr>
<tr>
<td>7–15 mg Fe/g dw</td>
<td>6 (10.0)</td>
</tr>
<tr>
<td>15–30 mg Fe/g dw</td>
<td>13 (21.7)</td>
</tr>
<tr>
<td>≥30 mg Fe/g dw</td>
<td>41 (68.3)</td>
</tr>
</tbody>
</table>

**Median serum ferritin (range), ng/mL** 5551 (1163–11,317)

Values are mean ± SD unless otherwise stated. †Recruited across seven countries (Turkey n=18; Egypt n=15; Italy n=14; Thailand n=7; United Kingdom n=3; Greece n=2; Taiwan n=1); ‡One patient received DFO for 180 months (22.6 mg/kg) plus DFX for 50 months (42 mg/kg) and one patient received 1 week on DFO–deferiprone combination therapy, followed by 1 week on DFX–DFO combination therapy for a total of 4 months; DFO (50 mg/kg), deferiprone (96 mg/kg), DFX (40 mg/kg).

DBA, Diamond–Blackfan anemia; DFO, deferoxamine; DFX, deferasirox; LIC, liver iron concentration, LVEF, left ventricular ejection fraction; mT2*, myocardial T2*; SD, standard deviation.
Table 2. Summary of mT2* improvements by baseline iron burden in patients treated with DFX–DFO combination followed by DFX monotherapy for 24 months

<table>
<thead>
<tr>
<th>Time point</th>
<th>Baseline LIC &lt;30 mg Fe/g dw</th>
<th>Baseline LIC ≥30 mg Fe/g dw</th>
<th>Baseline serum ferritin ≤2500 ng/mL</th>
<th>Baseline serum ferritin &gt;2500 ng/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>n=19</td>
<td>n=41</td>
<td>n=7</td>
<td>n=53</td>
</tr>
<tr>
<td>Gmean&lt;sub&gt;baseline&lt;/sub&gt; mT2*</td>
<td>8.04</td>
<td>6.83</td>
<td>7.81</td>
<td>7.12</td>
</tr>
<tr>
<td>(95% CI), ms</td>
<td>(7.39, 8.75)</td>
<td>(6.43, 7.26)</td>
<td>(6.36, 9.60)</td>
<td>(6.74, 7.52)</td>
</tr>
<tr>
<td>Month 24</td>
<td>n=15</td>
<td>n=21</td>
<td>n=6</td>
<td>n=30</td>
</tr>
<tr>
<td>Gmean&lt;sub&gt;24&lt;/sub&gt; mT2*</td>
<td>10.59</td>
<td>8.78</td>
<td>10.49</td>
<td>9.31</td>
</tr>
<tr>
<td>(95% CI), ms</td>
<td>(8.90, 12.61)</td>
<td>(7.55, 10.23)</td>
<td>(7.80, 14.10)</td>
<td>(8.18, 10.59)</td>
</tr>
<tr>
<td>Gmean ratio of Month 24/baseline (95% CI)</td>
<td>1.35</td>
<td>1.26</td>
<td>1.40</td>
<td>1.28</td>
</tr>
<tr>
<td></td>
<td>(1.16, 1.58)</td>
<td>(1.09, 1.45)</td>
<td>(1.07, 1.82)</td>
<td>(1.14, 1.43)</td>
</tr>
</tbody>
</table>

CI, confidence interval; DFO, deferoxamine; DFX, deferasirox; dw, dry weight; LIC, liver iron concentration; mT2*, myocardial T2*
Table 3. Summary of AEs regardless of relationship to study drug in patients treated with DFX–DFO in combination followed by DFX monotherapy over 24 months

<table>
<thead>
<tr>
<th>AE, n (%)</th>
<th>All patients n=60 (24 months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with any AE(s)</td>
<td>54 (90.0)</td>
</tr>
<tr>
<td>Discontinued as a result of AEs</td>
<td>5 (8.3)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>2 (3.3)</td>
</tr>
<tr>
<td>Arthritis</td>
<td>1 (1.7)</td>
</tr>
<tr>
<td>DRESS†</td>
<td>1 (1.7)</td>
</tr>
<tr>
<td>Pruritus</td>
<td>1 (1.7)</td>
</tr>
<tr>
<td>AEs leading to dose adjustment or interruption (≥5% of patients)</td>
<td>29 (48.3)</td>
</tr>
<tr>
<td>UPCR increase</td>
<td>6 (10.0)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>5 (8.3)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>5 (8.3)</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>4 (6.7)</td>
</tr>
<tr>
<td>Nausea</td>
<td>3 (5.0)</td>
</tr>
<tr>
<td>Influenza</td>
<td>3 (5.0)</td>
</tr>
<tr>
<td>Blood creatinine increase</td>
<td>3 (5.0)</td>
</tr>
</tbody>
</table>

†Suspected by the investigator. This case has been further evaluated by independent experts with no consensus for the diagnosis of DRESS syndrome.

AE, adverse event; DFO, deferoxamine; DFX, deferasirox; DRESS, drug rash with eosinophilia and systemic symptoms; UPCR, urinary protein/creatinine ratio.
Figure legends

Figure 1. Patient disposition

†A patient could have multiple reasons for screening failure.
‡The primary efficacy endpoint was assessed using the full analysis set.
§Five patients from Egypt and one patient from Italy.
¶Adverse events that led to discontinuation were abdominal pain (2), arthritis (1), drug rash with eosinophilia and systemic symptoms (1) and pruritus (1).
††Four patients had mT2* <6 ms at baseline, and one patient had mT2* of 6.1 ms at study entry.
‡‡Last available value within Month 12 window included in efficacy analysis, with exception of Month 12 mT2* where last observation carried forward (LOCF) was used.
‡‡Two patients were measured within the Month 24 window and were included in efficacy analyses, but failed to complete the full 24 months.

Figure 2. Mean daily dose in patients treated with DFX–DFO in combination followed by DFX monotherapy over 24 months

The length of the box represents the interquartile range (distance between the 25th and 75th percentiles), the whiskers extend to the 10th and 90th percentile. The means are presented as dots. DFO, deferoxamine; DFX, deferasirox.

Figure 3. mT2* and LIC in patients treated with DFX–DFO in combination followed by DFX monotherapy over 24 months

†Month value was the last available value within each visit window, eg Days 1–210, 211–390, 391–570 and 571–750 for Months 6, 12, 18 and 24, respectively, with the exception of Month 12
mT2* where last observation carried forward was used. Hence, although 34 patients completed 24 months, 36 or 35 patients had an mT2* or LIC measurement within the visit window.

CI, confidence interval; DFO, deferoxamine; DFX, deferasirox; dw, dry weight; LIC, liver iron concentration; mT2*, myocardial T2*; SD, standard deviation

Figure 4. The proportion of patients achieving mT2* ≥10 ms and ≥10% relative increase from baseline when treated with DFX–DFO combination followed by DFX monotherapy over 24 months

†Last observation carried forward.

CI, confidence interval; DFO, deferoxamine; DFX, deferasirox; FAS, full analysis set (patients who remained on treatment with an available assessment within each visit window); ITT, intent-to-treat (including all patients enrolled); mT2*, myocardial T2*.

Figure 5. Serum ferritin levels in patients treated with DFX–DFO in combination followed by DFX monotherapy over 24 months

BL, baseline. Error bars represent 25th and 75th percentiles.

Figure 6. ALT in patients treated with DFX–DFO in combination followed by DFX monotherapy over 24 months

ALT, alanine aminotransferase; SD, standard deviation.
Screened, n=312

Enrolled with baseline analyses, n=60 (19.2%)

Excluded† n=252
- Unacceptable test procedure result(s), n=98
- Did not meet diagnostic/severity criteria, n=97
- Unacceptable laboratory value(s), n=44
- Subject withdrew consent, n=11
- Other, n=3
- Unacceptable past medical history/concomitant diagnosis, n=1

Discontinued n=26
- Consent withdrawal, n=6
- Lost to follow-up, n=6§
- Adverse event, n=5||
- Abnormal test procedure (two consecutive cardiac T2* values <5 ms), n=5¶
- Administrative error, n=2
- Protocol deviation, n=1
- Death (pyrexia and altered state of consciousness), n=1

Completed 12 months, n=39 (65.0%)
- Analyzed for efficacy, n=46 (n=52; LOCF)††

Completed 24 months, n=34 (56.7%)
- Analyzed for efficacy, n=36‡‡

Analyzed for efficacy; n=60; Analyzed for safety, n=60
Figure 3

For personal use only.on April 1, 2017. by guest www.bloodjournal.orgFrom
<table>
<thead>
<tr>
<th>Time (months)</th>
<th>FAS</th>
<th>ITT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>47.2% (17/36) [95% CI: 32.0, 63.0]</td>
<td>33.3% (11/33) [95% CI: 19.8, 50.4]</td>
</tr>
<tr>
<td>6</td>
<td>12.5% (6/48) [95% CI: 5.9, 24.7]</td>
<td>19.2% (10/52) [95% CI: 10.8, 31.9]</td>
</tr>
<tr>
<td>12</td>
<td>16.7% (10/60) [95% CI: 9.3, 28.0]</td>
<td>18.3% (11/60) [95% CI: 10.6, 29.9]</td>
</tr>
<tr>
<td>18</td>
<td>28.3% (17/60) [95% CI: 18.5, 40.8]</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>28.3% (17/60) [95% CI: 18.5, 40.8]</td>
<td></td>
</tr>
</tbody>
</table>

Proportion of patients with T2* ≥10 ms and ≥10% increase from baseline (%)

Figure 4
Figure 5
Figure 6

For personal use only. On April 1, 2017, by guest

www.bloodjournal.org

Mean ± SD ALT (U/L) vs Time (months)
Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload

Yesim Aydinok, Antonis Kattamis, M. Domenica Cappellini, Amal El-Beshlawy, Raffaella Origa, Mohsen Elalfy, Yurdanur Kilinç, Silverio Perrotta, Zeynep Karakas, Vip Viprakasit, Dany Habr, Niculae Constantinovici, Junwu Shen and John B. Porter